The Health Ministry has proposed two amendments aimed at updating the country’s drug import framework, with changes expected to streamline procedures and strengthen regulatory oversight of pharmaceutical imports.
The proposed revisions seek to address existing challenges in the import approval process while improving efficiency for pharmaceutical companies and ensuring that imported medicines continue to meet required safety and quality standards.
Officials said the amendments are part of ongoing efforts to modernise drug regulations and create a more transparent system for managing the entry of medicines and related products into the market.
The changes could impact areas such as import approvals, compliance requirements, and regulatory processes followed by manufacturers, distributors, and importers.
Industry stakeholders have welcomed moves to improve the drug import framework, noting that clearer regulations and faster processes could support smoother supply chains while maintaining strict quality controls.
The proposed amendments come as the pharmaceutical sector continues to expand, with increasing demand for medicines, specialised treatments, and global healthcare products.
Further consultations and regulatory reviews are expected before the amendments are formally implemented.